10 completed, 1 recruiting, 1 terminated, 1 unknown. 4 Phase 3, 3 Phase 4, 2 Not applicable, 1 Early Phase 1, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 4 |
| Phase 4 | 3 | Completed 2, Recruiting 1 |
| Not applicable | 2 | Completed 1, Unknown 1 |
| Early Phase 1 | 1 | Completed 1 |
| Phase 1 | 1 | Terminated 1 |
Follow gadoteridol: new trials by email Literature Review of gadoteridol trials Research Report on gadoteridol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems) Gadoquatrane (BAY1747846), Gadobutrol, Gadoterate meglumine - Contrast Enhancement in Magnetic Resonance Imaging, Non-central Nervous System Pathology | Phase 3 | Completed | Bayer | 410 | 2023-07-24 | 2026-08-20 |
| A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related Problems Gadoquatrane (BAY1747846), Gadobutrol, Gadoterate meglumine - Contrast Enhancement in Magnetic Resonance Imaging, Central Nervous System Pathology | Phase 3 | Completed | Bayer | 321 | 2023-07-24 | 2026-10-08 |
| Novel Imaging Markers in SPMS Ferumoxytol infusion, Gadoteridol, MRI Brain and Cervical Spine - Secondary Progressive Multiple Sclerosis, Multiple Sclerosis, Secondary Progressive | Early Phase 1 | Completed | University of Utah | 11 | 2022-06-01 | 2026-08-13 |
| Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years Motor Tests, Cognitive Tests, Unenhanced-MRI of the brain - Motor Function, Cognitive Function | Phase 4 | Recruiting | Guerbet | 2076 | 2021-03-24 | 2026-01-22 |
| Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a Surgical Resection OS2966, Gadoteridol - Glioma, Malignant, High Grade Glioma | Phase 1 | Terminated | OncoSynergy, Inc. | 7 | 2021-03-02 | 2023-08-18 |
| Evaluation of Safety and Efficacy of ProHance in Pediatric Patients <2yrs ProHance - Central Nervous System Diseases, Central Nervous System Neoplasms | Completed | Bracco Diagnostics, Inc | 125 | 2018-11-01 | 2020-01-23 | |
| Meningeal Inflammation on 7T MRI as a Tool for Measuring and Predicting Ocrelizumab Response in Multiple Sclerosis Gadoteridol - Multiple Sclerosis | Completed | University of Maryland, Baltimore | 24 | 2018-09-24 | 2024-02-28 | |
| Baseline Cortical Haemodynamics in MS Magnetic Resonance Imaging, Prohance (Gadoteridol) - Multiple Sclerosis | Not applicable | Unknown | University of Nottingham | 80 | 2017-01-01 | 2018-10-12 |
| Steady State Blood Volume Maps Using Ferumoxytol Non-stoichiometric Magnetite MRI in Imaging Patients With Glioblastoma Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging, Ferumoxytol, Gadoteridol - Glioblastoma | Not applicable | Completed | OHSU Knight Cancer Institute | 29 | 2015-01-06 | 2022-03-17 |
| Comparison of Prohance® With Gadovist®/Gadavist™ in Magnetic Resonance Imaging (MRI) of the Brain gadoteridol, gadobutrol - Brain Disease | Phase 4 | Completed | Bracco Diagnostics, Inc | 229 | 2012-08-01 | 2015-07-01 |
| Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D) Regadenoson myocardial perfusion imaging, Regadenoson MRI myocardial blood flow - Coronary Artery Disease, Type 1 Diabetes Mellitus | Phase 4 | Completed | University of Colorado, Denver | 26 | 2009-11-01 | 2015-12-14 |
| Safety and Efficacy of Gadobutrol 1.0 Molar (Gadavist) in Patients for Central Nervous System (CNS) Imaging Gadobutrol (Gadavist, Gadovist, BAY86-4875), Gadoteridol (ProHance) - Diagnostic Imaging, Central Nervous System Diseases | Phase 3 | Completed | Bayer | 402 | 2008-06-01 | 2014-12-30 |
| SH L 562BB Phase II/III Dose Justification and Gadoteridol-controlled Comparative Study Gadobutrol (Gadavist, Gadovist, BAY86-4875), ProHance - Brain Metastases | Phase 3 | Completed | Bayer | 165 | 2007-08-01 | 2017-08-28 |
Multiple Sclerosis (3) · Central Nervous System Diseases (2) · Glioblastoma (2) · Astrocytoma (1) · Brain Diseases (1) · Brain Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Central Nervous System Neoplasms (1) · Colorectal Neoplasms (1) · Coronary Artery Disease (1) · Diabetes Mellitus, Type 1 (1) · Glioma (1) · Multiple Sclerosis, Chronic Progressive (1) · Neuroendocrine Tumors (1)
Bayer (4) · Bracco Diagnostics, Inc (2) · Guerbet (1) · OHSU Knight Cancer Institute (1) · OncoSynergy, Inc. (1) · University of Colorado, Denver (1) · University of Maryland, Baltimore (1) · University of Nottingham (1) · University of Utah (1)
United States (11) · Germany (4) · Japan (4) · Canada (3) · France (3) · Italy (3) · South Korea (3) · United Kingdom (3) · Argentina (2) · Bulgaria (2) · China (2) · Czechia (2) · Hungary (2) · Sweden (2) · Turkey (Türkiye) (2)
Gianpaolo Pirovano, MD (2) · Daniel M Harrison, M.D. (1) · Edward A Neuwelt (1) · M. Mateo Paz Soldan, MD, PhD (1) · Nikos Evangelou, Ph.D. (1) · Robert A. Quaife, M.D (1)
UL1TR002538 (1)